Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Jun;26(6):353-7.
doi: 10.1155/2012/725468.

Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Melanie D Beaton  1
Affiliations
Review

Current treatment options for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Melanie D Beaton. Can J Gastroenterol. 2012 Jun.

Abstract
in English, French

Nonalcoholic fatty liver disease is the leading cause of liver disease in western society. It is a cause of end-stage liver disease, with increased mortality secondary to cirrhosis and its complications. It is also recognized that cardiovascular disease is a significant cause of death in these patients. Significant work evaluating various treatments has been performed in recent years; however, to date, no ideal therapy exists. Lifestyle modification remains the cornerstone of management. The present article reviews the current status of various treatment modalities evaluated in nonalcoholic fatty liver disease.

La stéatohépatose non alcoolique est la principale cause de maladie hépatique dans la société occidentale. Elle est responsable de maladies hépatiques en phase terminale, et une mortalité accrue est imputable à la cirrhose et à ses complications. Il est également convenu que les maladies cardiovasculaires sont une importante cause de décès chez ces patients. Ces dernières années, on a effectué des travaux importants afin d’évaluer les divers traitements, mais jusqu’à maintenant, il n’existe aucun traitement idéal. Les modifications au mode de vie demeurent la pierre angulaire de la prise en charge. Le présent article permet d’analyser l’état actuel des diverses modalités thérapeutiques évaluées en cas de stéatohépatose non alcoolique.

PubMed Disclaimer

References

    1. Alfire ME, Treem WR. Nonalcoholic fatty liver disease. Pediatr Ann. 2006;35:290–4. - PubMed
    1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity. Hepatology. 2004;40:1387–95. - PubMed
    1. Improving the Health of Canadians, Canadian Population Health Initiative, Canadian Institute for Health Information, 2004
    1. McCullough AJ. The epidemiology and risk factors for NASH. In: Farrell CG, George J, de la M Hall P, McCullough AJ, editors. Fatty Liver Disease: NASH and Related Disorders. Malden: Blackwell Publishing; 2005. pp. 23–37.
    1. Creutzfeldt W, Frerichs H, Sickinger K. Liver diseases and diabetes mellitus. Prog Liver Dis. 1970;3:371–407. - PubMed

LinkOut - more resources